Vasoactive Intestinal Polypeptide in the respiratory tract: Physiology and pathophysiology;Vasoaktives Intestinales Polypeptid (VIP) im atemtrakt: Physiologie und pathophysiologie

Pneumologie

Volumn 58, Issue 5, 2004, Pages 330-338

  Groneberg, D A ^a   Rabe, K F ^b   Wagner, U ^c   Fischer, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BOSENTAN; CALCIUM ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; RECEPTOR SUBTYPE; SILDENAFIL; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ASTHMA; BRONCHUS; DUODENUM; ENZYME ACTIVITY; LIFE EXPECTANCY; LOWER RESPIRATORY TRACT; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFLAMMATION; REVIEW; TRACHEA; UPPER RESPIRATORY TRACT; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANTI-INFLAMMATORY AGENTS; HUMANS; RESPIRATORY PHYSIOLOGY; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASES; VASOACTIVE INTESTINAL PEPTIDE;

EID: 2542582260     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818352     Document Type: Review

References (132)

1. 331 1 Barnes PJ. Asthma as an axon reflex. Lancet 1986; 1: 242-245
2. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825-857
3. Gozes I, Fridkin M, Brenneman DE. A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Cell Mol Neurobiol 1995; 15: 675-687
4. Eynott PR, Groneberg DA, Caramori G et al. Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness. Eur J Pharmacol 2002; 452: 123-133
5. Eynott PR, Paavolainen N, Groneberg DA et al. Role of nitric oxide in chronic allergen-induced airway cell proliferation and inflammation. J Pharmacol Exp Ther 2003; 304: 22-29
6. Joos GF, Pauwels RA. Tachykinin receptor antagonists: potential in airways diseases. Curr Opin Pharmacol 2001; 1: 235-241
7. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515-596
8. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002; 302: 839-845
9. Velden VH van der, Hulsmann AR. Autonomic innervation of human airways: structure, function, and pathophysiology in asthma. Neuroimmunomodulation 1999; 6: 145-159
10. Widdicombe JG. Autonomic regulation. i-NANC/e-NANC. Am J Respir Crit Care Med 1998; 158: S171-175
11. Linden A. NANC neural control of airway smooth muscle tone. Gen Pharmacol 1996; 27: 1109-1121
12. Widdicombe JG. Overview of neural pathways in allergy and asthma. Pulm Pharmacol Ther 2003; 16: 23-30
13. Belvisi MG. Sensory nerves and airway inflammation: role of A delta and C-fibres. Pulm Pharmacol Ther 2003; 16: 1-7
14. Groneberg DA, Springer J, Fischer A. Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 2001; 14: 391-401
15. Bedoui S, Kawamura N, Straub RH et al. Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol 2003; 134: 1-11
16. Fischer A, Folkerts G, Geppetti P et al. Mediators of asthma: nitric oxide. Pulm Pharmacol Ther 2002; 15: 73-81
17. Groneberg DA, Fischer A. Endogenous opioids as mediators of asthma. Pulm Pharmacol Ther 2001; 14: 383-389
18. Goetzl EJ, Voice JK, Shen S et al. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 2001; 98: 13 854-13 859
19. Fischer TC, Hartmann P, Loser C et al. Abundant expression of vasoactive intestinal polypeptide receptor VPAC2 mRNA in human skin. J Invest Dermatol 2001; 117: 754-756
20. Said SI, Mutt V. A peptide fraction from lung tissue with prolonged peripheral vasodilator activity. Scand J Clin Lab Invest Suppl 1969; 107: 51-56
21. Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970; 225: 863-864
22. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169: 1217-1218
23. Gozes I, Nakai H, Byers M et al. Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24. Somat Cell Mol Genet 1987; 13: 305-313
24. Gozes I, Brenneman DE. VIP: molecular biology and neurobiological function. Mol Neurobiol 1989; 3: 201-236
25. Lilly CM, Drazen JM, Shore SA. Peptidase modulation of airway effects of neuropeptides. Proc Soc Exp Biol Med 1993; 203: 388-404
26. Hachisu M, Hiranuma T, Tani S et al. Enzymatic degradation of helodermin and vasoactive intestinal polypeptide. J Pharmacobiodyn 1991; 14: 126-131
27. Lundberg JM, Fahrenkrug J, Hokfelt T et al. Co-existence of peptide HI (PHI) and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man. Peptides 1984; 5: 593-606
28. Baraniuk JN, Lundgren JD, Okayama M et al. Vasoactive intestinal peptide in human nasal mucosa. J Clin Invest 1990; 86: 825-831
29. Bowden JJ, Gibbins IL. Vasoactive intestinal peptide and neuropeptide Y coexist in non-noradrenergic sympathetic neurons to guinea pig trachea. J Auton Nerv Syst 1992; 38: 1-19
30. Fischer A, Hoffmann B. Nitric oxide synthase in neurons and nerve fibers of lower airways and in vagal sensory ganglia of man. Correlation with neuropeptides. Am J Respir Crit Care Med 1996; 154: 209-216
31. Carstairs JR, Barnes PJ. Visualization of vasoactive intestinal peptide receptors in human and guinea pig lung. J Pharmacol Exp Ther 1986; 239: 249-255
32. Ishihara T, Shigemoto R, Mori K et al. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992; 8: 811-819
33. Lutz EM, Sheward WJ, West KM et al. The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1993; 334: 3-8
34. Ciccarelli E, Vilardaga JP, de Neef P et al. Properties of the VIP-PACAP type II receptor stably expressed in CHO cells. Regul Pept 1994; 54: 397-407
35. Rawlings SR, Piuz I, Schlegel W et al. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs. Endocrinology 1995; 136: 2088-2098
36. Harmar AJ, Arimura A, Gozes I et al. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50: 265-270
37. Couvineau A, Rouyer-Fessard C, Darmoul D et al. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 1994; 200: 769-776
38. Couvineau A, Rouyer-Fessard C, Maoret JJ et al. Vasoactive intestinal peptide (VIP)1 receptor. Three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J Biol Chem 1996; 271: 12795-12800
39. Sreedharan SP, Patel DR, Huang JX et al. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Commun 1993; 193: 546-553
40. Gourlet P, Vandermeers A, Vertongen P et al. Development of high affinity selective VIP1 receptor agonists. Peptides 1997; 18: 1539-1545
41. Gourlet P, de Neef P, Cnudde J et al. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 1997; 18: 1555-1560
42. Inagaki N, Yoshida H, Mizuta M et al. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci U S A 1994; 91: 2679-2683
43. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994; 135: 2662-2680
44. Svoboda M, Tastenoy M, van Rampelbergh J et al. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem Biophys Res Commun 1994; 205: 1617-1624
45. Wei Y, Mojsov S. Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol 1996; 8: 811-817
46. Gourlet P, Vertongen P, Vandermeers A et al. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 1997; 18: 403-408
47. O'Donnell M, Garippa RJ, Rinaldi N et al. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther 1994; 270: 1282-1288
48. O'Donnell M, Garippa RJ, Rinaldi N et al. Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther 1994; 270: 1289-1294
49. Tang H, Welton A, Ganea D. Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553. J Interferon Cytokine Res 1995; 15: 993-1003
50. Xia M, Sreedharan SP, Bolin DR et al. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 1997; 281: 629-633
51. Fischer TC, Dinh QT, Peiser C et al. Simultaneous detection of receptor mRNA and ligand protein in human skin tissues. J Cutan Pathol 2002; 29: 65-71
52. Groneberg DA, Hartmann P, Dinh QT et al. Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. Lab Invest 2001; 81: 749-755
53. Busto R, Prieto JC, Bodega G et al. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 2000; 21: 265-269
54. Peiser C, Springer J, Groneberg DA et al. Leptin receptor expression in nodose ganglion cells projecting to the rat gastric fundus. Neurosci Lett 2002; 320: 41-44
55. Fischer A, Kummer W, Couraud JY et al. Immunohistochemical localization of receptors for vasoactive intestinal peptide and substance P in human trachea. Lab Invest 1992; 67: 387-393
56. Voice JK, Dorsam G, Lee H et al. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J 2001; 15: 2489-2496
57. Palmer JB, Cuss FM, Barnes PJ. VIP and PHM and their role in non-adrenergic inhibitory responses in isolated human airways. J Appl Physiol 1986; 61: 1322-1328
58. Altiere RJ, Diamond L. Comparison of vasoactive intestinal peptide and isoproterenol relaxant effects in isolated cat airways. J Appl Physiol 1984; 56: 986-992
59. Hand JM, Uravuso RB, Will JA. Relaxation of isolated guinea pig trachea, bronchi and pulmonary arteries produced by vasoactive intestinal peptide(VIP). Eur J Pharmacol 1984; 98: 279-284
60. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984; 97: 304-310
61. Diamond L, Szarek JL, Gillespie MN et al. In vivo bronchodilator activity of vasoactive intestinal peptide in the cat. Am Rev Respir Dis 1983; 128: 827-832
62. Hamasaki Y, Saga T, Mojarad M et al. Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery. Trans Assoc Am Physicians 1983; 96: 406-411
63. Boornsma JD, Said SI. The role of neuropeptides in asthma. Chest 1992; 101: 389S-392S
64. Cox CP, Lerner MR, Wells JJ et al. Inhaled vasoactive intestinal peptide (VIP) prevents bronchoconstriction induced by inhaled histamine. Am Rev Respir Dis 1983; 127: A249
65. Bundgaard A, Enehjelm SD, Aggestrup S. Pretreatment of exercise-induced asthma with inhaled vasoactive intestinal peptide (VIP). Eur J Respir Dis Suppl 1983; 128: 427-429
66. Altiere RJ, Kung M, Diamond L. Comparative effects of inhaled isoproterenol and vasoactive intestinal peptide on histamine-induced bronchoconstriction in human subjects. Chest 1984; 86: 153-154
67. Morice A, Unwin RJ, Sever PS. Vasoactive intestinal peptide causes bronchodilatation and protects against histamine-induced bronchoconstriction in asthmatic subjects. Lancet 1983; 2: 1225-1227
68. Groneberg DA, Nickolaus M, Springer J et al. Localization of the peptide transporter PEPT2 in the lung: implications for pulmonary oligopeptide uptake. Am J Pathol 2001; 158: 707-714
69. Groneberg DA, Eynott PR, Doring F et al. Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax 2002; 57: 55-60
70. Groneberg DA. Expression, Lokalisation und funktionelle Aspekte des Peptidtransporters PEPT2 im gesunden Atemtrakt und bei Mukoviszidose. Pneumologie 2003; 57: 104-105
71. Groneberg DA, Doring F, Nickolaus M et al. Expression of PEPT2 peptide transporter mRNA and protein in glial cells of rat dorsal root ganglia. Neurosci Lett 2001; 304: 181-184
72. Sharaf H, Said S. I. Tracheal relaxant response to vasoactive intestinal peptide (VIP): influence of airway epithelium and peptidases (abstract). FASEB J 1993; 7: A686
73. Bolin DR, Cottrell J, Garippa R et al. Structure-activity studies of vasoactive intestinal peptide (VIP): cyclic disulfide analogs. Int J Pept Protein Res 1993; 41: 124-132
74. Ito O, Tachibana S. Vasoactive intestinal polypeptide precursors have highly potent bronchodilatory activity. Peptides 1991; 12: 131-137
75. Schmidt DT, Ruhlmann E, Waldeck B et al. The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 314-320
76. Lung MA, Widdicombe JG. Lung reflexes and nasal vascular resistance in the anaesthetized dog. J Physiol (Lond) 1987; 386: 465-474
77. Lundberg JM, Anggard A, Emson P et al. Vasoactive intestinal polypeptide and cholinergic mechanisms in cat nasal mucosa: studies on choline acetyltransferase and release of vasoactive intestinal polypeptide. Proc Natl Acad Sci U S A 1981; 78: 5255-5259
78. Laitinen LA, Laitinen A, Salonen RO et al. Vascular actions of airway neuropepticles. Am Rev Respir Dis 1987; 136: S59-64
79. Hamasaki Y, Mojarad M, Said SI. Relaxant action of VIP on cat pulmonary artery: comparison with acetylcholine, isoproterenol, and PGE1. J Appl Physiol 1983; 54: 1607-1611
80. Nandiwada PA, Kadowitz PJ, Said SI et al. Pulmonary vasodilator responses to vasoactive intestinal peptide in the cat. J Appl Physiol 1985; 58: 1723-1728
81. Obara H, Kusunoki M, Mori M et al. The effects of various peptides on the isolated pulmonary artery. Peptides 1989; 10: 241-243
82. Matran R, Alving K, Martling CR et al. Effects of neuropeptides and capsaicin on tracheobronchial blood flow of the pig. Acta Physiol Scand 1989; 135: 335-342
83. Greenberg B, Rhoden K, Barnes PJ. Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries. Blood Vessels 1987; 24: 45-50
84. Barnes PJ, Cadieux A, Carstairs JR et al. Vasoactive intestinal peptide in bovine pulmonary artery: localisation, function and receptor autoradiography. Br J Pharmacol 1986; 89: 157-162
85. Groneberg DA, Peiser C, Dinh QT et al. Distribution of respiratory mucin proteins in human nasal mucosa. Laryngoscope 2003; 113: 520-524
86. Groneberg DA, Eynott PR, Oates T et al. Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung. Respir Med 2002; 96: 81-86
87. Groneberg DA, Eynott PR, Lim S et al. Expression of respiratory mucins in fatal status asthmaticus and mild asthma. Histopathology 2002; 40: 367-373
88. Groneberg DA, Wagner U, Chung KF. Mucus and fatal asthma. Am J Med 2004; 116: 66-67
89. Dey RD, Shannon Jr WA, Said SI. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res 1981; 220: 231-238
90. Peatfield AC, Barnes PJ, Bratcher C et al. Vasoactive intestinal peptide stimulates tracheal submucosal gland secretion in ferret. Am Rev Respir Dis 1983; 128: 89-93
91. Wagner U, Bredenbroker D, Storm B et al. Effects of VIP and related peptides on airway mucus secretion from isolated rat trachea. Peptides 1998; 19: 241-245
92. Webber SE, Widdicombe JG. The effect of vasoactive intestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea. Br J Pharmacol 1987; 91: 139-148
93. Shimura S, Sisaki T, Ikeda K et al. VIP augments cholinergic-induced glycoconjugate secretion in tracheal submucosal glands. J Appl Physiol 1988; 65: 2537-2544
94. Nathanson I, Widdicombe JH, Barnes PJ. Effect of vasoactive intestinal peptide on ion transport across dog tracheal epithelium. J Appl Physiol 1983; 55: 1844-1848
95. Richardson PS, Webber SE. The control of mucous secretion in the airways by peptidergic mechanisms. Am Rev Respir Dis 1987; 136: S72-76
96. Sakai N, Tamaoki J, Kobayashi K et al. Vasoactive intestinal peptide stimulates ciliary motility in rabbit tracheal epithelium: modulation by neutral endopeptidase. Regul Pept 1991; 34: 33-41
97. Coles SJ, Said SI, Reid LM. Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro. Am Rev Respir Dis 1981; 124: 531-536
98. Goetzl EJ, Pankhaniya RR, Gaufo GO et al. Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses. Ann N Y Acad Sci 1998; 840: 540-550
99. Said SI, Dickman KG. Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Regul Pept 2000; 93: 21-29
100. Nio DA, Moylan RN, Roche JK. Modulation of T lymphocyte function by neuropeptides. Evidence for their role as local immunoregulatory elements. J Immunol 1993; 150: 5281-5288
101. Undem BJ, Dick EC, Buckner CK. Inhibition by vasoactive intestinal peptide of antigen-induced histamine release from guinea-pig minced lung. Eur J Pharmacol 1983; 88: 247-250
102. O'Dorisio MS, Shannon BT, Fleshman DJ et al. Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage. J Immunol 1989; 142: 3533-3536
103. Berisha H, Foda H, Sakakibara H et al. Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase. Am J Physiol 1990; 259: L151-155
104. Misra BR, Misra HP. Vasoactive intestinal peptide, a singlet oxygen quencher. J Biol Chem 1990; 265: 15371-15374
105. Leceta J, Gomariz RP, Martinez C et al. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci 2000; 921: 92-102
106. Delgado M, Abad C, Martinez C et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 563-568
107. Groneberg DA, Welker P, Fischer TC et al. Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol 2003; 111: 1099-1105
108. Ollerenshaw S, Jarvis D, Woolcock A et al. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med 1989; 320: 1244-1248
109. Howarth PH, Djukanovic R, Wilson JW et al. Mucosal nerves in endobronchial biopsies in asthma and non-asthma. Int Arch Allergy Appl Immunol 1991; 94: 330-333
110. Howarth PH, Springall DR, Redington AE et al. Neuropeptide-containing nerves in endobronchial biopsies from asthmatic and nonasthmatic subjects. Am J Respir Cell Mol Biol 1995; 13: 288-296
111. Chanez P, Springall D, Vignola AM et al. Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med 1998; 158: 985-990
112. Kaltreider HB, Ichikawa S, Byrd PK et al. Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am J Respir Cell Mol Biol 1997; 16: 133-144
113. Barnes PJ. Vasoactive intestinal peptide and asthma. N Engl J Med 1989; 321: 1128-1129
114. Wenzel SE, Fowler AAd, Schwartz LB. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am Rev Respir Dis 1988; 137: 1002-1008
115. Paul S, Said SI, Thompson AB et al. Characterization of autoantibodies to vasoactive intestinal peptide in asthma. J Neuroimmunol 1989; 23: 133-142
116. Ohzeki T, Ishitani N, Hanaki K et al. Responses of plasma vasoactive intestinal polypeptide to methacholine and exercise loading in children and adolescents with bronchial asthma. Pediatr Allergy Immunol 1993; 4: 26-29
117. Cardell LO, Uddman R, Edvinsson L. Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma. Eur Respir J 1994; 7: 2169-2173
118. Palmer JB, Cuss FM, Warren JB et al. Effect of infused vasoactive intestinal peptide on airway function in normal subjects. Thorax 1986; 41: 663-666
119. Barnes PJ, Dixon CM. The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis 1984; 130: 162-166
120. Linden A, Hansson L, Andersson A et al. Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax 2003; 58: 217-221
121. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-1544
122. Olschewski H, Ghofrani A, Wiedemann R et al. Pulmonaler Hochdruck. Internist (Berl) 2002; 43: 1498, 1501-1509
123. Olschewski H, Seeger W. Behandlung der Pulmonal Arteriellen Hypertonie. Pneumologie 2000; 54: 222-224
124. Ghofrani HA, Olschewski H, Seeger W et al. Sildenafil zur Therapie der schweren pulmonalen Hypertonie und des beginnenden Rechtsherzversagens. Pneumologie 2002; 56: 665-672
125. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-164
126. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81
127. Keith IM. The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol Res 2000; 49: 519-537
128. Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-1346
129. Jones AS. Non-allergic perennial rhinitis. Biomed Pharmacother 1988; 42: 499-503
130. Groneberg DA, Heppt W, Cryer A et al. Toxic rhinitis-induced changes of human nasal mucosa innervation. Toxicol Pathol 2003; 31: 326-331
131. Heppt W, Peiser C, Cryer A et al. Innervation of human nasal mucosa in environmentally triggered hyperreflectoric rhinitis. J Occup Environ Med 2002; 44: 924-929
132. Groneberg DA, Heppt W, Welker P et al. Aspirin-sensitive rhinitis associated changes in upper airway innervation. Eur Respir J 2003; 22: 986-991